Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Cash & Equivalents (2016 - 2025)

ProQR Therapeutics' Cash & Equivalents history spans 6 years, with the latest figure at $107.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 32.62% to $107.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $107.6 million, a 32.62% decrease, with the full-year FY2025 number at $107.6 million, down 32.62% from a year prior.
  • Cash & Equivalents hit $107.6 million in Q4 2025 for ProQR Therapeutics, down from $159.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PRQR hit a ceiling of $214.5 million in Q4 2021 and a floor of $91.3 million in Q2 2021.
  • Historically, Cash & Equivalents has averaged $137.9 million across 5 years, with a median of $135.6 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: soared 137.25% in 2021 and later crashed 54.93% in 2022.
  • Tracing PRQR's Cash & Equivalents over 5 years: stood at $214.5 million in 2021, then plummeted by 54.93% to $96.7 million in 2022, then soared by 32.33% to $128.0 million in 2023, then rose by 24.77% to $159.7 million in 2024, then crashed by 32.62% to $107.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for PRQR at $107.6 million in Q4 2025, $159.7 million in Q4 2024, and $128.0 million in Q4 2023.